Global Hemostasis Diagnostics Market – Industry Trends and Forecast to 2029

Global Hemostasis Diagnostics Market, By Product (Laboratory Analyzers, Consumables, Point-of-Care Testing Systems), Test Type (Activated Partial Thromboplastin Time, D Dimer Test, Fibrinogen Test, Prothrombin Time (PT) Test, Activated Clotting Time, Platelet Aggregation Test), End Use (Hospitals/Clinics, Independent Diagnostic Laboratories, Home Care Settings, Others) – Industry Trends and Forecast to 2029.

Hemostasis Diagnostics Market Analysis and Size

Hemostasis diagnostics is a procedure which helps in the detection of hemostatic defects that cause excessive bleeding. The body uses hemostasis as a defence mechanism when it sustains damage. It also helps in the diagnosis of actual cause of these disorders with history and helps in the treatment.

Data Bridge Market Research analyses that the hemostasis diagnostics market which was USD 5.90 million in 2021, is expected to reach USD 11.42 million by 2029, at a CAGR of 8.60% during the forecast period 2022 to 2029. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Hemostasis Diagnostics Market Scope and Segmentation      

Market Definition

Hemostasis is a protective process that the body uses when it is injured. It reduces the blood loss and stops blood flow. The body uses hemostasis as a defence mechanism when it sustains injury. Hemostasis helps with both the treatment of numerous illnesses and the identification of their true causes. From assessing the optical density in a cuvette to spotting clotting factors, hemostasis diagnostics have come a long way.

Global Hemostasis Diagnostics Market Dynamics

Drivers

• Rise in hemophilia

Rising incidences of blood clotting diagnosis for patients, particularly those who are more prone to losing excess blood from the body during surgeries, are major factors driving market growth. According to the National Hemophilia Foundation, haemophilia affected approximately 400,000 people in 2019, and approximately 75% of people with haemophilia around the world continue to receive inadequate treatment or do not have access to treatment. As a result, the market's growth is influenced positively.

• Technological developments

Raising awareness about hemostasis conditions is expected to improve diagnostic rates and preventive care management, resulting in a significant increase in testing volume. The advancement of technology has resulted in the introduction of many novel diagnostic systems and tests, such as the introduction of automated blood coagulation analyzers, which will provide a significant growth opportunity for this market in the coming years.

Opportunities

• Increase in Point-of-Care testing system

Patients and clinicians are more likely to use point-of-care diagnostic tests and rising patient awareness of POC processes is driving market growth. Furthermore, one of the driver is the efficient use of POC devices for diagnosis by minimally skilled professionals. POC development initiatives are also supported by a number of private organizations, including the California Institute of Technology, Dartmouth College, and international organisations. For instance, to enhance professionals' diagnostic testing outside of clinical laboratories, the American Association for Clinical Chemistry developed a certification programme in August 2018. As a result, the market is anticipated to increase profitably during the forecast period.

Restraints/Challenges

• Stringent government regulations

Stringent government regulation and lack of awareness regarding hemostasis disorders in underdeveloped regions will obstruct the market's growth rate.

This hemostasis diagnostics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hemostasis diagnostics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Hemostasis Diagnostics Market Scope

The hemostasis diagnostics market is segmented on the basis of product, test type and end use. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Laboratory Analyzers
• Point-of-Care Testing Systems

 Test Type

• Activated Partial Thromboplastin Time
• D Dimer Test
• Fibrinogen Test
• Prothrombin Time (PT) Test
• Activated Clotting Time
• Platelet Aggregation Test

End Use

• Hospitals
• Diagnostic Centers
• Others

Hemostasis Diagnostics Market Regional Analysis/Insights

The hemostasis diagnostics market is analysed and market size insights and trends are provided by country, product, test type and end use as referenced above.

The countries covered in the hemostasis diagnostics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the hemostasis diagnostics market due to the rising prevalence of surgeries, increasing R&D activities and organ transplant procedures and developed healthcare infrastructure in the region.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 owing to the rising awareness regarding hemostasis.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Hemostasis Diagnostics Market Share Analysis

The hemostasis diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to hemostasis diagnostics market.

Some of the major players operating in the hemostasis diagnostics market are:

• Abbott (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• HORIBA Europe Holding (Japan)
• Medtronic (Ireland)
• Technidyne Corporation (U.S.)
• BD (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• NIHON KOHDEN CORPORATION (Japan)
• Haemonetics Corporation (U.S.)
• Beckman Coulter Inc. (U.S.)
• Chrono-log Corporation (U.S.)
• Sysmex Corporation (Japan)
• Siemens (Germany)
• Danaher (U.S.)
• Grifols S.A. (Spain)